0.3497
price up icon0.20%   0.0007
after-market Dopo l'orario di chiusura: .34 -0.0097 -2.77%
loading
Precedente Chiudi:
$0.349
Aprire:
$0.345
Volume 24 ore:
352.93K
Relative Volume:
0.28
Capitalizzazione di mercato:
$61.89M
Reddito:
-
Utile/perdita netta:
$-32.54M
Rapporto P/E:
-1.7485
EPS:
-0.2
Flusso di cassa netto:
$-29.06M
1 W Prestazione:
-10.43%
1M Prestazione:
-19.42%
6M Prestazione:
-50.40%
1 anno Prestazione:
-54.94%
Intervallo 1D:
Value
$0.3413
$0.3599
Intervallo di 1 settimana:
Value
$0.3413
$0.42
Portata 52W:
Value
$0.33
$1.07

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name
Nome
Citius Pharmaceuticals Inc
Name
Telefono
(908) 967-6676
Name
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Name
Dipendente
22
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-12
Name
Ultimi documenti SEC
Name
CTXR's Discussions on Twitter

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-11-30 Iniziato Maxim Group Buy

Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie

pulisher
Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India

Oct 24, 2024
pulisher
Oct 17, 2024

CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com

Oct 17, 2024
pulisher
Oct 15, 2024

Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex

Oct 14, 2024
pulisher
Oct 10, 2024

There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 08, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Is Citius Pharmaceuticals Inc (CTXR) a threat to investors? - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Market Resilience: Citius Pharmaceuticals Inc (CTXR) Finishes Weak at 0.43, Down -2.60 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Point72 DIFC Ltd Makes New $29,000 Investment in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World

Oct 04, 2024
pulisher
Oct 02, 2024

Citius Pharmaceuticals Inc (CTXR) can make a big difference with a little luck - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Oct 01, 2024
pulisher
Sep 30, 2024

Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Citius Pharmaceuticals Inc’s results are impressive - US Post News

Sep 30, 2024
pulisher
Sep 28, 2024

Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa

Sep 28, 2024
pulisher
Sep 27, 2024

Citius Pharmaceuticals extends executive and warrant agreements - Investing.com

Sep 27, 2024
pulisher
Sep 26, 2024

Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cettire shares skyrocket - ShareCafe

Sep 24, 2024
pulisher
Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

Sep 23, 2024
pulisher
Sep 21, 2024

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

Sep 21, 2024
pulisher
Sep 17, 2024

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Sep 17, 2024
pulisher
Sep 17, 2024

Citius Pharmaceuticals Inc (CTXR)’s Day in Review: Closing at 0.50, Down by -2.90 - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News

Sep 17, 2024
pulisher
Sep 16, 2024

Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News

Sep 16, 2024
pulisher
Sep 13, 2024

Citius Pharmaceuticals defers FDA milestone payment - Investing.com

Sep 13, 2024
pulisher
Sep 13, 2024

Citius Pharmaceuticals defers FDA milestone payment By Investing.com - Investing.com UK

Sep 13, 2024
pulisher
Sep 13, 2024

Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Sep 13, 2024
pulisher
Sep 13, 2024

Financial Metrics Check: Citius Pharmaceuticals Inc (CTXR)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 13, 2024
pulisher
Sep 12, 2024

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com India

Sep 12, 2024
pulisher
Sep 12, 2024

Citius Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Australia

Sep 12, 2024
pulisher
Sep 09, 2024

Insider’s View: Deciphering Citius Pharmaceuticals Inc (CTXR)’s Financial Health Through Ratios - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

Can you still get a good price for Citius Pharmaceuticals Inc (CTXR) Shares at this point? - US Post News

Sep 09, 2024
pulisher
Sep 06, 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Sep 06, 2024
pulisher
Sep 06, 2024

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - The Malaysian Reserve

Sep 06, 2024
pulisher
Sep 05, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Malaysian Reserve

Sep 05, 2024

Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):